HealthCare Global Enterprises Beneficio por dividendo

¿Qué es el Beneficio por dividendo de HealthCare Global Enterprises?

El Beneficio por dividendo de HealthCare Global Enterprises Limited es N/A

¿Cuál es la definición de Beneficio por dividendo?

El rendimiento de dividendos representa la relación entre los dividendos pagados a los accionistas por acción y el precio de mercado por acción durante un año final.

The dividend yield or dividend-price ratio of a share is the dividend per share, divided by the price per share. It is also a company's total annual dividend payments divided by its market capitalization, assuming the number of shares is constant, and is often expressed as a percentage. The reciprocal of the dividend yield is the price-dividend ratio.

A higher dividend yield has been considered to be desirable among many investors. A high dividend yield can be considered to be evidence that a stock is underpriced or that the company has fallen on hard times and future dividends will not be as high as previous ones. Similarly a low dividend yield can be considered evidence that the stock is overpriced or that future dividends might be higher. Some investors may find a higher dividend yield attractive, for instance as an aid to marketing a fund to retail investors, or maybe because they cannot get their hands on the capital, which may be tied up in a trust arrangement. In contrast some investors may find a higher dividend yield unattractive, perhaps because it increases their tax bill.

¿Qué hace HealthCare Global Enterprises?

HealthCare Global Enterprises Limited, together with its subsidiaries, provides healthcare services focusing on cancer and fertility. The company offers cancer diagnosis and treatment services through radiation therapy, medical oncology, and surgery; and fertility treatment services, as well as reproductive medicine services, including assisted reproduction, gynecological endoscopy, and fertility preservation under the Milann brand. It also operates four multi-specialty hospitals, including three under the HCG brand in Ahmedabad, Bhavnagar, and Rajkot in the state of Gujarat, as well as one under operations and management contract in Hubli in the state of Karnataka that primarily provide cardiology, neurology, orthopedics, gastroenterology, urology, internal medicine, and pulmonary and critical care. In addition, the company offers medical diagnostic services, including scientific testing and consultancy services in the pharmaceutical and medical sector. As of March 31, 2022, the company operated 22 comprehensive cancer centers, including 1 center in Africa. The company was founded in 1989 and is based in Bengaluru, India.